Blood based Alzheimer tests ….so far

There has been no solid clinical documentation or applicability, and numberous studies have failed to document any clinical relevance related to measuring beta-amyloid directly in the blood.

further, there are—

•Multiple independent assays (protein/RNA) and complex bioinformatics

•Unstable diagnostic tools with overly optimistic and unrealistic diagnostic models

•Limited links to known disease pathology

•Few additional blood-based technologies  lacking solid clinical documentation

•Cultivated blood cells, various approaches

•Numerous studies have failed documenting any clinical relevance of measuring beta-amyloid directly in blood


Against this backdrop of trial and error, Pre Diagnostic will produce a new ELISA-test using conventional technologies and instrumentation linked directly to the Alzheimer pathology.

PreDx biomarker – the funnelling test to more invasive and expensive procedures